NCT02307240View on ClinicalTrials.gov

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Triple-Negative Breast CancerHigh-grade Serous Ovarian CancerSolid TumorsNUT Midline Carcinoma
Interventions
DRUG

CUDC-907

CUDC-907 oral with meals.

Trial Locations (4)

34232

Florida Cancer Specialists, Sarasota

77030

The University of Texas MD Anderson Cancer Center, Houston

94143

UCSF School of Medicine, San Francisco

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Curis, Inc.

INDUSTRY

NCT02307240 - Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Biotech Hunter | Biotech Hunter